2024 SABCS Highlights

CME

CCO Independent Conference Highlights of the 2024 San Antonio Breast Cancer Symposium

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: March 04, 2025

Expiration: September 03, 2025

Activity

Progress
1 2
Course Completed

Introduction

In this module, Heather McArthur, MD, MPH, and Joyce O’Shaughnessy, MD, discuss key studies for breast cancer that were presented at the 2024 San Antonio Breast Cancer Symposium (SABCS 2024), with a focus on new clinical research of interest and clinical trial updates.

Please note that the slide thumbnails in this activity link to PowerPoint slidesets, each focused on the specific study or topic of interest. These slidesets may be downloaded by clicking on any of the thumbnails within the activity.

Please note that Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with breast cancer do you provide care for in a typical month?

In exploratory analyses presented at SABCS 2024 for the phase III NATALEE trial evaluating adjuvant therapy with ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) vs an NSAI alone in patients with stage II/III, hormone receptor (HR)–positive/HER2-negative early breast cancer (EBC), investigators explored the impact of dose reductions from 400 mg QD to 200 mg QD on treatment efficacy. In consultation with a patient, which of the following would you say most accurately reflects the impact of ribociclib dose reduction on invasive disease–free survival (IDFS) in the NATALEE trial?

The phase III EMBER-3 trial is comparing imlunestrant with or without abemaciclib vs standard-of-care (SoC) endocrine therapy (ET) (exemestane or fulvestrant) in patients with advanced breast cancer (ABC) or metastatic breast cancer (mBC) and disease progression during or after aromatase inhibitor (AI) treatment, with or without a CDK4/6 inhibitor, in the adjuvant setting or as first-line treatment for ABC/mBC. In the analysis presented at SABCS 2024 for this study, which of the following accurately reflects the median progression-free survival (mPFS) outcomes with imlunestrant plus abemaciclib vs imlunestrant alone in the intention-to-treat (ITT) and ESR1-mutant populations?

Which of the following findings was reported from the randomized, open-label phase III PATINA study evaluating the efficacy and safety of palbociclib combined with SoC anti-HER2 therapy plus ET vs anti-HER2 therapy plus ET alone after induction treatment in patients with HR-positive/HER2-positive mBC?

Based on the data presented for the phase III KEYNOTE-522 trial at SABCS 2024, which of the following biomarkers selectively correlated with higher pathologic complete response (pCR) rates and longer event-free survival (EFS) with the use of (neo)adjuvant pembrolizumab plus chemotherapy vs (neo)adjuvant chemotherapy alone?